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Abstract
Many recent evidences indicate that androgen-sensitive prostate cancer cells have a lower malignant phenotype that is in particular
characterized by a reduced migration and invasion. We previously demonstrated that expression of androgen receptor (AR) by transfection
of the androgen-independent prostate cancer cell line PC3 decreases invasion and adhesion of these cells (PC3-AR) through modulation
of 64 integrin expression. The treatment with the synthetic androgen R1881 further reduced invasion of the cells without, however,
modifying 64 expression on the cell surface, suggesting an interference with the invasion process in response to EGF. We investigated
whether the presence of the AR could affect EGF receptor (EGFR)-mediated signaling in response to EGF by evaluating autotransphos-
phorylation of the receptor as well as activation of downstream signalling pathways. Immunoprecipitation studies demonstrated a reduction
of EGF-induced tyrosine phosphorylation of EGFR in PC3-AR cells. In addition, EGF-stimulated PI3K activity, a key signalling pathway
for invasion of these cells, was decreased in PC3-AR cells and further reduced by treatment with R1881, indicating decreased function-
ality of EGFR. An interaction between EGFR and AR has been demonstrated by immunoconfocal and co-immunoprecipitation analysis
in PC3-AR cells, suggesting a possible interference of AR on EGFR signalling by interaction of the two proteins. In conclusion, our
results suggest that the expression of AR by transfection in PC3 cells confers a less malignant phenotype by interfering with EGFR
autophosphorylation and signalling in response to EGF leading to invasion through a mechanism involving an interaction between AR and
EGFR.
© 2004 Elsevier Inc. All rights reserved.
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1. Introduction
Prostate cancer (PC) is the most common malignancy
detected in men in western countries [1,2]. Although en-
docrine therapy is very useful when surgery is not feasible
and leads to substantial periods of remission, progression
from androgen dependence to independence always occurs
in treated patients. Androgen-independent PC cells are in-
sensitive to endocrine treatment and continue to grow and
invade.
One of the striking characteristics of androgen-inde-
pendent PC is represented by its higher invasive potential
and malignant phenotype [3,4], that is in particular charac-
terized by an increased migration and invasion. This pheno-
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type, at least in part, can be explained by loss of androgen
control of genes involved in limiting invasion [5].
We previously demonstrated that expression of androgen
receptor (AR) by transfection of the androgen-independent
prostate cancer cell line PC3, decreases adhesion, anchorage-
independent growth and EGF-mediated Matrigel invasion
of these cells (PC3-AR) respect to control cells (PC3-Neo,
transfected only with the vector) through reduced expres-
sion of 64 integrin [3]. Similar results have been obtained
by another group in a different cell line [4]. The treatment
with the synthetic androgen R1881 further reduced Ma-
trigel invasion of the cells [3,4], however, we have been
unable to demonstrate an effect of the synthetic androgen
on 64 expression on the cell surface [3], thus suggesting
an alternative mechanism for decreasing invasive potential
of the cells in vitro. We have thus evaluated the effect of the
androgen on EGF-mediated signalling pathways leading to
invasion in PC3-Neo and PC3-AR cells.
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Fig. 1. Western blot analysis of PC3-Neo and PC3-AR cell total lysates using an anti-phosphotyrosine antibody (PY20) and an anti-EGF receptor antibody
(anti-EGFR). Cells were stimulated or not with EGF (50 ng/ml, 10 min) in the presence or absence of the synthetic androgen R1881 (1 nM for 24 h). C:
no stimulation.
1.1. EGFR autotransphopshorylation is reduced in
PC3-AR cells
By Western blotting analysis, we examined tyrosine phos-
phorylation of EGFR in response to EGF. As shown in
Fig. 1 tyrosine phosphorylation of EGFR in response to EGF
was reduced in PC3-AR cells when R1881 was present.
This result was also confirmed after EGFR immunoprecipi-
tation and probing with anti-phosphotyrosine antibody (not
shown). To ensure that EGFR expression was similar in
PC3-AR and PC3-Neo cells, surface expression of the re-
ceptor was evaluated by FACScan analysis, which demon-
strated no difference in EGFR expression in the two cell
lines (not shown).
Overall, this result suggests an interference of the andro-
gen with signalling pathways in response to EGF in PC3-AR
cells.
1.2. The androgen receptor (AR) co-localize with EGFR at
the plasma membrane
Emerging evidences indicate that besides its classical
localization at the nuclear level, the AR may be targeted
at the membrane level where interactions with proteins
involved in growth factor signaling, such as src kinase fam-
ily members [6], caveolin-1 [7] and PI3K [8] have been
demonstrated. These studies prompted us to investigate
whether AR can interact with EGFR in our cell line. The
localization of AR and EGFR was investigated by confocal
laser microscopy in PC3-AR cells stained for both pro-
teins. As shown in Fig. 2, the AR (in red, middle panels)
localizes both to the nucleus and the cytoplasm of PC3-AR
cells, although after stimulation with R1881, increased lo-
cation to the nuclei was evident. Interestingly, a striking
co-localization (in yellow, right panels) of the AR with the
EGFR (in green, left panels) at the plasma membrane level
was present. No staining for AR was present in PC3-Neo
cells (not shown). Co-immunoprecipitation studies, con-
ducted in PC3-AR cells, confirmed interaction between the
two proteins. Indeed, after immunoprecipitation with an
antibody against EGFR, a band at 110 kDa was detected by
immunoblot analysis with an anti-AR antibody in PC3-AR
cells (not shown). Co-immunoprecipitation between the
EGFR and AR was also detected in the androgen-sensitive
cell line LNCaP (not shown). Of interest, in this cell line,
re-probing the membrane with an antibody against phos-
photyrosine residues demonstrated that the treatment with
R1881 determined a decrease in EGFR autophosphory-
lation in response to EGF. Overall, these results suggest
that an interaction between EGFR and AR occurring in
androgen-sensitive prostate carcinoma cells may be involved
in determining the lower invasive potential of these cells
[3,4].
Fig. 2. Immunoconfocal analysis of the androgen receptor and the EGF
receptor in PC3-AR cells. Cells pre-treated or not with the synthetic
androgen R1881 (1 nM, 24 h), were plated on laminin-1 for 2 h and then
stimulated with EGF (50 ng/ml) or vehicle (C) for 10 min. Cells were
permeabilized and processed for double staining with rabbit polyclonal
anti-AR (N-20) (red) and anti-EGFR (Ab-1) (green) antibodies. Yellow
depicts co-localization of the two antibodies.
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Fig. 3. PI3K activity in PC3-Neo and PC3-AR cells. Cells were stimulated or not with EGF (50 ng/ml, 10 min) in the presence or absence of the synthetic
androgen R1881 (1 nM for 24 h) and PI3K activity evaluated by immunokinase assay (13). Panel A: Mean ± S.E.M. values of PI3K activity (arbitrary
units) in four different experiments performed in the two cell lines. Panel B: Typical experiment performed in PC3-AR cells. PIP: phosphatodylinositol
phosphate.
1.3. EGF-mediated PI3-kinase activation is reduced in
PC3-AR cells
As mentioned above, EGF promotes the activation of dis-
tinct signaling pathways in cancer cells, including PI3K
which finally leads to migration and metastasis [9]. To eval-
uate whether PI3K activation is involved in Matrigel inva-
sion of PC3-Neo cells, invasion assays were performed in
the absence or presence of the PI3K inhibitor LY294002
(80M). We found that EGF-induced invasion through Ma-
trigel was totally inhibited by the pretreatment (30 min) with
LY294002 (not shown) indicating that the activation of PI3K
pathway is essential for EGF-dependent invasion. To investi-
gate whether PI3K activity was altered in PC3-AR cells, cell
lysates from PC3-Neo and PC3-AR cells plated on laminin
and stimulated or not with EGF (50 ng/ml) were immuno-
precipitated with an anti-phosphotyrosine antibody to re-
cruit the activated fraction of PI3K and assayed for their
ability to phosphorylate l--phosphatidylinositol. As shown
in Fig. 3A, which reports mean ± S.E.M. values of PI3K
activity (measured by quantification of the bands) of four
different experiments, both basal and EGF-stimulated PI3K
activity are reduced in PC3-AR cells respect to PC3-Neo.
Pre-treatment with R1881 determined a further decrease of
EGF-stimulated PI3K activity in PC3-AR cells, whereas it
was ineffective in PC3-Neo cells. Fig. 3B shows a typical
experiment performed in PC3-AR cells. This result suggests
that in the presence of the androgen receptor PI3K activ-
ity was reduced in line with the recent results demonstrat-
ing that the lost of androgens sensitivity such as in high
passages LNCaP cells [10] and androgen-refractory LNCaP
cells following androgen deprivation [11], leads to higher
activity of PI3K respect to cells expressing a more differen-
tiated phenotype, such as LNCaP cells at the early passages
or androgen-sensitive LNCaP cells which maintain a much
lower PI3K activity.
2. Conclusions
Androgen-insensitive prostate cancer cells are charac-
terized by increased growth, adhesion, invasion and mi-
gration [1–4]. We show here that an interaction between
the AR and the EGFR at the membrane level occurs in
androgen-sensitive prostate cancer cell lines and show evi-
dence that the reduced invasive properties of these cells are
due to an interaction between the EGFR and AR, decreased
signalling leading to EGFR autotransphosphorylation and
lower PI3K activation in response to EGF. Whether this
interaction is responsible for the reduced PI3K activity
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detected in PC3-AR cells needs to be investigated, in any
case our results suggest that in the presence of the androgen
receptor PI3K activity was reduced according to the recent
results demonstrating that the lost of androgens sensitivity
leads to higher activity of PI3K respect to cells expressing a
more differentiated phenotype, such as LNCaP cells at the
early passages or androgen-sensitive LNCaP cells which
maintain a much lower PI3K activity [10,11]. The inter-
action between the AR and EGFR as well as the reduced
functionality of EGFR in PC3-AR cells leads to the hypoth-
esis that membrane localization of the complex between
AR-EGFR may determine a sequestration of the EGFR.
Whether the interaction between AR and EGFR is due
to direct binding of the two proteins or is mediated by an-
other protein needs to be investigated further. It is known
from previous studies that AR is able to interact directly
with c-src [6] and with PI3K [8]. In particular, the interac-
tion with c-src is mediated by a proline-rich region present
in the DNA binding domain of the receptor [6]. It is thus
possible that another protein, able to interact with both the
AR and the EGFR could mediate the interaction found in
our experiments.
In conclusion, in androgen-sensitive prostate carcinoma
cells the AR, localized at the plasma membrane, contribute
to confer a less malignant phenotype of these cells both by
reducing the expression and function of alpha6beta4 [3] and
by interfering with EGFR signalling leading to invasion in
response to EGF through a co-localization and interaction
between AR and EGFR at the membrane [12].
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